Mr. Fetcho has been involved with early stage and start-up companies for the last 15 years. He has been a co-founder in multiple companies, including a revolutionary packaging technology that sustains the life of produce and flowers while in transit all while killing off food-borne pathogens. Sean has worked alongside major politicians and leading sustainability organizations around the world to develop strategies around fighting global hunger. In the healthcare industry, Sean successfully created, launched and oversaw a highly profitable set of print and digital publications, targeting oncology, pain management and cardiology professionals. Most recently with PAINWeek, Sean developed new revenue streams that helped structure the business for an exit. Within 3 years, PAINWeek sold to a public company traded on the London Stock Exchange. From this experience within the analgesics and co-morbidities in pain space, he quickly realized the opioid epidemic is rapidly growing and that the world is seeking change. He believed Alternative Therapy treatments will be the future and farm bill compliant hemp can be one of these groundbreaking solutions. Verséa was then conceptualized between the founders. Sean attended University of Westminster and Towson University with degrees in Economics & Psychology. He participated in Columbia University’s School of Business training programs for executives and advanced training in Neuro-Linguistic Programming, Urgency-Based Selling, Strategic Intuition, Management, Sales and Business Development.
Co-Founder, Chief Operating Officer Steve Porada Mr. Porada has over 30 years of pharmaceutical research and commercialization experience and is a co-founder of Verséa Holdings. He began his career as a research scientist at Ciba-Geigy, now Novartis, and later held a variety of sales, marketing and commercialization positions at pharmaceutical and medical device companies. In 2004 Stephen’s entrepreneurial experience began with joining Aventine Co, a startup medical marketing and communications company focused in the therapeutic area of pain. Stephen, as partner, directly engaged with, consulted on, and established a variety of commercial-related plans and strategies spanning 12 unique analgesic brands. His work included preapproval clinical trial and market development plans, tactical new formulation development, multi-partner commercial planning, strategic marketing, launch planning and implementation. In addition to his work related to product commercialization, Stephen conceptualized and founded Aventine’s primary asset, PAINWeek, which was ultimately sold to Tarsus, a publicly traded company on the London Stock Exchange.
“Dr Toby” is also the Chief Medical Officer of Summit Institute and Desert Clinic Pain Institute that has 17 locations in Southern California. Prior to going into private practice, he held an appointment as associate clinical professor of anesthesiology and psychiatry and as the director of clinical pain research at the University of California San Diego. He is double-board certified in Anesthesiology and Pain Management and became an assistant clinical professor and enrolled in the masters program for clinical research. He joined the VA San Diego Healthcare System and established his pain clinic there serving the Veteran population. Dr. Toby also serves as the Director of Research with Vitamed Research, LLC., conducting research projects and trials in the field of pain and neurosciences. Dr. Toby served as the director for clinical pain research at UCSD, is well published and is an associate clinical professor (voluntary) with the University of California Riverside School of Medicine. Toby was part of the founding team of Verséa, where he understands that there is an unmet need to further the science of the Endocannabinoid System to find solutions for patients looking for alternative therapy treatments.
Mr Alfaras comes to Verséa as a Proven Leader in Pharma, Biotech and Healthcare as a C-Suite Executive with a demonstratedhistory of success and Skilled Leadership in Pharmaceutical, Biotechnology, Medical Device, Strategic Planning and Business Development. Carlos has served as President & CEO of Gensco Pharma beginning January of 2011. Since the acquisition, the company has developed and launched five new products based on Patented Transdermal drug delivery technology and increased market valuation to over $200MM under his direction. Carlos has been Head of Business Development, Bioniche Pharma (Acquired by Mylan Specialty), Senior Director Alternate Care and Business Development, ANDA Pharmaceuticals/ANDRX Corporation (Acquired by WATSON Pharmaceuticals), Executive Director, Head of Business Strategy and Global Development ANDA/Watson Pharmaceuticals (Acquired by TEVA) . He attended theUniversity of Miami, majoring in Biology/Pre-Medical studies and utilized this education and experience to enter the pharmaceutical management world. In his dedication for the pursuit of excellence, he has had successes in creating growth in revenues at every company he has been associated with through education, team building, strategic planning and efficiently determining the development strategies for all.
Mr. Olin comes to Versea as a proven executive with over twenty-five years of leadership experience in brand marketing, sales, commercial development and general management. He was most recently the President & CEO of COM Holdings, LLC a private equity owned B2B2C platform company. Jim’s unique background combines the classical training of leadership roles at Unilever and Colgate-Palmolive, with senior executive positions in multiple high-growth entrepreneurial and private equity backed companies. An expert at building brands and commercial teams, having led some of the nation’s most iconic brands, Jim’s capabilities span the full range of commercial processes across diverse industries including health & beauty, personal care, nutritional supplements, nutraceuticals, integrative health, natural products. Jim resides in Maine with his wife, two daughters and their canine companions Mickey and Jeter.
Timmi has over 23 years of pharmaceutical experience in sales and marketing of both branded and generic products. In her varying roles, she has been involved in the development, launch and/or growth of brands in pain management, neurology, oncology, infectious disease, autoimmune disease and respiratory. Most recently, Timmi was the therapy strategy lead for emerging markets at OptumRx, where she developed go-to-market sales strategies for emerging therapies in their specialty pharmacy division. Prior to OptumRx, she led the marketing team for Scilex Pharmaceuticals, launching their first commercial product nationwide. Amongst her many roles prior to Scilex, Timmi was one of the founding members of Sentynl Therapeutics, where she re-launched a branded generic in the pain space and was instrumental in building and training their sales force. Timmi overseas all of the sales initiatives for Verséa Pharmaceuticals managing the US market.
Gary has over 23 years of pharmaceutical commercialization experience. He is the Founder and President of Sapient Pharmaceutical Advisors Inc., a consulting company targeting startup companies preparing for commercialization. Prior to this Gary was the Senior Director of Market Development at Depomed Pharmaceuticals and led the commercial development and execution of strategy for a portfolio of Pain and CNS brands including Cambia®, Zipsor®, Gralise®, Lazanda®, Nucynta®, Nucynta® ER and a new chemical entity cebranopadol. Gary was Senior Director of Marketing and successfully led the re-launch of the $1 billion-dollar acquisition of the Nucynta and Nucynta ER franchise. Prior to Depomed, Gary was Director of Marketing at Purdue Pharma L.P. overseeing the portfolio of pain products including MS Contin®, MSIR®, OxyContin®, OxyFAST®, OxyIR®, Dilaudid®, Dilaudid® HP, Palladone®, Ryzolt®, Butrans®, and Hysingla® ER. Gary is an experienced commercial leader who has overseen new product development ranging from Pre-clinical through Launch and Phase IV.
Senior, C-level executive with over 20 years of pharmaceutical and biotechnology industry experience in oncology, dermal, and pain drug development. Dr. Shah is the Chief Development Officer at WindMIL Therapeutics and Clinical Development consultant at TKL Research working on optimizing dermal and pain therapeutics. He was the Chief Operating Officer of IRX Therapeutics /Brooklyn ImmunoTherapeutics. Prior to that, he was the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb. Dr. Shah was Head of Clinical Operations and Development at Ventrus Biosciences working on their GI pain NCE/NME and 505(b)(2) portfolio prior to its merger with Assembly Biosciences. Prior to Ventrus, Dr. Shah led the solid tumor development programs and led the clinical portfolio and strategic planning function at Celgene Corporation. He led the Oncology Development and Operations activities at Fibrogen and Novacea. Dr. Shah began his career at Novartis in the Oncology Early Development Group leading clinical trials prior to joining the Medical Sciences Group at Amgen. Dr. Shah received his BS and PharmD degrees from Rutgers University in New Jersey and his MBA from Florida Institute of Technology.
Senior pharmaceutical R&D and regulatory executive with over 20 years of industry experience across major global markets with an underlying philosophy that R&D supports commercial. Highly experienced in determining and executing efficient and cost-effective global development program. Successful leadership in preparation and conduct of Agency meetings (PIND and equivalent, EOP1,EOP2, and PNDA/MAA and regional equivalents) obtaining agreement on data requirements for introducing pharmaceutical products to the clinic, progressing through development including conduct of pivotal studies, and preparation/submission of market applications. Regulatory strategy development includes obtaining orphan drug status, Fast Track status (and global equivalents), and accelerated approval for orphan indications and/or breakthrough therapies. Successful leadership in the execution of development programs through preclinical development to market approvals, and supporting commercial products (i.e., post-approval studies to support label changes, promotional materials, and CMC changes). Indications include oncology, analgesia, dermatology, gastrointestinal, cardiovascular, anti-infectives, and pulmonary/respiratory. Experience extends to NCE/NMEs, repurposed drugs (505(b)(2)/10(c) and equivalents), siRNAs, monoclonal antibodies, oligonucleotides, biologics, high-value generics, and over-the-counter (OTC) products (including novel dosage forms). Dosage forms include solid oral (including modified release), topical/transdermal (patches, creams, ointments, gels, etc.), sprays (oral and topical), inhalation, nasal, and parenteral. Lead in technical due diligence in both in-licensing and out-licensing business development, including M&A. Served as primary lead in technical due diligence on behalf of financial institutions (private equity, venture capital, investment banks).
Tony has 17-years of experience in the healthcare industry. He is a 10-year veteran of Eli Lilly with a proven track record of creating and executing direct-to-physician campaigns that grow market share and profits. He has a broad range of functional experience, from leading high-performance sales teams as a field-based sales rep and district sales manager, to improving sales effectiveness and efficiency as a brand manager and LEAN Six Sigma Black Belt. As a member of the Verséa team, Tony is applying his unique mix of experience and expertise to lead the demand generation segment of the marketing team: Creating sales messaging, training programs, and promotional campaigns to reach, acquire, and retain doctors, nurses, hospitals and other healthcare professionals (“Customers”) interested in purchasing Verséa products for distribution to individual consumers. Tony got his B.S. in Marketing from North Carolina A&T State University and his MBA at Northwestern’s Kellogg School of Management where he majored in finance, marketing and organizational behavior.
After receiving his BS (Pharmacy) and MS (Pharmacognosy) degrees, Jinhui Dou became a faculty member at Beijing University of Chinese Medicine and taught pharmacy classes for 4 years. He accepted a graduate assistantship from the Pharmacognosy Department at the University of Mississippi and received a PhD degree in 1996 from Dr. James McChesney, a distinguished professor of pharmacognosy. After working at the University of Kansas as a post-doc associate, he became a Natural Product Scientist at NaPro BioTherapeutics in December 1996. He led a group of chemists and engineers in the reduction of paclitaxel manufacturing costs and in the establishment of a library of related-substance reference standards to support the CMC, pharmacology, and toxicology sections of paclitaxel NDA and ANDA filings. Dr. Dou joined the FDA in 2002 as a pharmacologist reviewer in the Center for Drug Evaluation and Research (CDER). He reviewed anti-infective and anti-inflammatory chemical-drug filings for several years before working as a botanical reviewer full time. He was a CDER and Agency expert pharmacologist and pharmacognosist specialized in botanical drug review. Dr. Dou received numerous awards from CDER, FDA, and HHS for his distinguished contributions to the development of new drug guidances, policies, and regulations and his scientific reviews of new chemical and botanical drugs. After more than 15 years at the FDA, he now works as a chief advisor with Verséa Pharmaceuticals and provides consultations on cannabis chemistry, nonclinical and clinical development related projects for the clinical pathway and FDA advancements. Dr. Dou is a member of American Society of Pharmacognosy (ASP) and the NIH/NCI PDQ Integrative, Alternative, and Complementary Therapies (IACT) editorial board. His publications on anticancer, chemo-preventative, and anti-infective drugs or bioactive natural products, including lupin alkaloids, green tea, quassinoinds, and proanthocyanidins, are from his academia and industry research activities or FDA new drug review experience.